tarlatamab
Sponsor Amgen INC · listed as AMGN
tarlatamab is a drug asset sponsored by Amgen INC, listed as AMGN. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Jul 5, 2027 (day precision, medium confidence), tied to trial NCT06211036. That trial is in Phase 3 and currently active not recruiting, studying Extensive-Stage Small-Cell Lung Cancer. It appears across 6 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for tarlatamab
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2027-07-05 | READOUT | medium | NCT06211036 |
| 2027-09-24 | READOUT | medium | NCT07778316 |
Trials for tarlatamab in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT05740566 | Phase 3 | Active, not recruiting | 2025-01-29 | Experimental | Amgen | Small Cell Lung Cancer (SCLC) |
| NCT06211036 catalyst | Phase 3 | Active, not recruiting | 2027-07-05 | Experimental | Amgen | Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer |
| NCT07778316 catalyst | Phase 3 | Recruiting | 2027-09-24 | Experimental | Amgen | Small Cell Lung Cancer |
| NCT07005128 | Phase 3 | Active, not recruiting | 2029-01-04 | Experimental | Amgen | Small-cell Lung Cancer; Extensive Stage Small-cell Lung Cancer |
| NCT06117774 | Phase 3 | Active, not recruiting | 2030-04-20 | Experimental | Amgen | Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer |
| NCT07637513 | Phase 3 | Not yet recruiting | 2037-11 | Experimental | PrECOG, LLC. | Limited Stage Small-Cell Lung Cancer |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More AMGN catalysts